Compare InMode Ltd (INMD) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
InMode Ltd vs BIO-TECHNE Corp — how do they compare? InMode Ltd trades at $14.21 (market cap $809.93M), while BIO-TECHNE Corp trades at $72.46 (market cap $11.36B). The key difference: BIO-TECHNE Corp is far larger — about 14× InMode Ltd's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while InMode Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold InMode Ltd for 28 Days and BIO-TECHNE Corp for 64 Days on average.
| INMD | TECH | |
|---|---|---|
Market Cap | $809.93M | $11.36B |
Volume | 365,490 | 5,390,331 |
Sector | Health | Health |
52-Week High | $16.62 | $72.61 |
52-Week Low | $12.76 | $43.31 |
Typical Hold Time | 28 Days | 64 Days |
Enterprise Value | $313.27M | $11.39B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
InMode (INMD) trades at $14.08, up 0.5% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong profitability with 76.5% gross margins and 20.7% net income margin, though Q1 2026 earnings missed expectations. Recent developments include the launch of Morpheus8 Cool technology and an unsolicited acquisition offer from Steel Partners at $16.75 per share in July 2026.
Investment outlook is cautiously optimistic with attractive valuation metrics (P/E 11.6, EV/EBITDA 4.5) offset by near-term revenue stagnation. Key risks include US platform sales decline and management capital allocation concerns. Analyst consensus leans neutral with 45% buy ratings and 55% hold, suggesting potential upside if the acquisition materializes or international growth accelerates.
TECH trades at $72.45, near its 52-week high of $72.70 (Defense World, 2026-09-28), with a slight 0.11% decline over 24 hours. The stock shows a bullish technical signal, supported by moving averages, while fundamentals reveal a high P/E of 62.46 and net income margin of 14.97% for 2025. Recent news highlights shareholder approval of its acquisition by Merck KGaA at $73.00 per share (PRNewsWire, 2026-09-23), a key catalyst for near-term price action.
The outlook is mixed: the acquisition offers upside to the current price, but elevated valuation ratios pose risks if earnings growth falters. Analyst consensus is divided with 46% buy ratings, and net income volatility from 2022-2025 signals execution challenges. Investors should weigh the acquisition premium against fundamental sustainability in a competitive life sciences tools sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About InMode Ltd
InMode provides innovative medical technologies for minimally invasive surgical procedures. Its platforms use radiofrequency (RF) energy for aesthetic treatments like body contouring and skin tightening.
Read more on INMD →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
